Olivia C Leavy, Richard J Russell, Ewen M Harrison, Nazir I Lone, Steven Kerr, Annemarie B Docherty, Aziz Sheikh, Matthew Richardson, Omer Elneima, Neil J Greening, Victoria Claire Harris, Linzy Houchen-Wolloff, Hamish J C McAuley, Ruth M Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, Raminder Aul, Paul Beirne, Charlotte E Bolton, Jeremy S Brown, Gourab Choudhury, Nawar Diar Bakerly, Nicholas Easom, Carlos Echevarria, Jonathan Fuld, Nick Hart, John R Hurst, Mark Jones, Dhruv Parekh, Paul Pfeffer, Najib M Rahman, Sarah Rowland-Jones, Ajay M Shah, Dan G Wootton, Caroline Jolley, A A Roger Thompson, Trudie Chalder, Melanie J Davies, Anthony De Soyza, John R Geddes, William Greenhalf, Simon Heller, Luke Howard, Joseph Jacob, R Gisli Jenkins, Janet M Lord, Will D-C Man, Gerry P McCann, Stefan Neubauer, Peter J M Openshaw, Joanna Porter, Matthew J Rowland, Janet T Scott, Malcolm G Semple, Sally J Singh, David Thomas, Mark Toshner, Keir Lewis, Liam G Heaney, Andrew Briggs, Bang Zheng, Mathew Thorpe, Jennifer K Quint, James D Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krisnah Poinasamy, Betty Raman, Louise V Wain, Christopher E Brightling, Rachael A Evans
{"title":"1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.","authors":"Olivia C Leavy, Richard J Russell, Ewen M Harrison, Nazir I Lone, Steven Kerr, Annemarie B Docherty, Aziz Sheikh, Matthew Richardson, Omer Elneima, Neil J Greening, Victoria Claire Harris, Linzy Houchen-Wolloff, Hamish J C McAuley, Ruth M Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, Raminder Aul, Paul Beirne, Charlotte E Bolton, Jeremy S Brown, Gourab Choudhury, Nawar Diar Bakerly, Nicholas Easom, Carlos Echevarria, Jonathan Fuld, Nick Hart, John R Hurst, Mark Jones, Dhruv Parekh, Paul Pfeffer, Najib M Rahman, Sarah Rowland-Jones, Ajay M Shah, Dan G Wootton, Caroline Jolley, A A Roger Thompson, Trudie Chalder, Melanie J Davies, Anthony De Soyza, John R Geddes, William Greenhalf, Simon Heller, Luke Howard, Joseph Jacob, R Gisli Jenkins, Janet M Lord, Will D-C Man, Gerry P McCann, Stefan Neubauer, Peter J M Openshaw, Joanna Porter, Matthew J Rowland, Janet T Scott, Malcolm G Semple, Sally J Singh, David Thomas, Mark Toshner, Keir Lewis, Liam G Heaney, Andrew Briggs, Bang Zheng, Mathew Thorpe, Jennifer K Quint, James D Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krisnah Poinasamy, Betty Raman, Louise V Wain, Christopher E Brightling, Rachael A Evans","doi":"10.1183/23120541.00474-2024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) 1 year after discharge.</p><p><strong>Methods: </strong>Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies (Post-hospitalisation COVID-19 and the International Severe Acute Respiratory and emerging Infection Consortium). HRQoL, assessed by the EuroQol-Five Dimensions-Five Levels utility index (EQ-5D-5L UI), pre-hospital and 1 year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient-reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias.</p><p><strong>Findings: </strong>Of the 1888 participants included in the primary analysis, 1149 received corticosteroids. There was no between-group difference in EQ-5D-5L UI at 1 year (mean difference 0.004, 95% CI -0.026-0.034). A similar reduction in EQ-5D-5L UI was seen at 1 year between corticosteroid exposed and nonexposed groups (mean±sd change -0.12±0.22 <i>versus</i> -0.11±0.22). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a cohort of 109 318 patients admitted to hospital with COVID-19, EQ-5D-5L UI at 1 year remained similar between the two groups.</p><p><strong>Interpretation: </strong>Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL 1 year after hospital discharge. Treatments to address the persistent reduction in HRQoL are urgently needed.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440406/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/23120541.00474-2024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) 1 year after discharge.
Methods: Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies (Post-hospitalisation COVID-19 and the International Severe Acute Respiratory and emerging Infection Consortium). HRQoL, assessed by the EuroQol-Five Dimensions-Five Levels utility index (EQ-5D-5L UI), pre-hospital and 1 year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient-reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias.
Findings: Of the 1888 participants included in the primary analysis, 1149 received corticosteroids. There was no between-group difference in EQ-5D-5L UI at 1 year (mean difference 0.004, 95% CI -0.026-0.034). A similar reduction in EQ-5D-5L UI was seen at 1 year between corticosteroid exposed and nonexposed groups (mean±sd change -0.12±0.22 versus -0.11±0.22). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a cohort of 109 318 patients admitted to hospital with COVID-19, EQ-5D-5L UI at 1 year remained similar between the two groups.
Interpretation: Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL 1 year after hospital discharge. Treatments to address the persistent reduction in HRQoL are urgently needed.
期刊介绍：
ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
